Almost 20% of the Market Value for Pharmaceuticals in 2005 (From About 16 Products) Faces Generic Competition by Mid 2008.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47802) has announced the addition of The Billion-Dollar Question: Which Emerging Agents Have Blockbuster Potential to their offering. In 2005, more than half of the $405 billion worldwide pharmaceutical market was generated from sales of more than 100 blockbuster products. From the beginning of 2006 through mid 2008, however, 19 of these agents (20% of blockbuster sales) will face patent expiry. The potential generic threat from these expiries poses a challenge for both the companies that manufacture them and the industry at large. Questions Answered in This Spectrum Report Almost 20% of the market value for pharmaceuticals in 2005 (from about 16 products) faces generic competition by mid 2008. What are the top blockbuster drugs facing challenges from patent expiries? What agents are manufacturers developing in an effort to fill this void? We forecast that eight new blockbuster products will launch between the end of 2006 and mid 2008. What approaches will these new drugs take in addressing their respective indications? How successful will these emerging agents be in these indications? The new crop of blockbusters slated to debut in the next few years will bring new players to the list of blockbuster-producing companies. Which companies will become new members of the blockbuster club? How will their approaches in creating and sustaining these drugs differ from those taken by other companies that have created blockbusters? Scope Blockbusters introduction: current state of the $1 billion+ drug category. Metabolic indications covered: type 2 diabetes type 2 diabetes n. See diabetes mellitus. , metabolic syndrome metabolic syndrome n. See syndrome X. Metabolic syndrome A group of risk factors for heart disease, diabetes, and stroke. , and obesity. Psychiatric indications covered: schizophrenia, bipolar mania, and major depression. Other indications: Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , atherosclerosis atherosclerosis (ăth'ərōsklərō`sĭs): see arteriosclerosis. atherosclerosis or hardening of the arteries , coronary heart disease coronary heart disease: see coronary artery disease. coronary heart disease or ischemic heart disease Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). , postmyocardial nfarction, rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. , Crohn's disease Crohn's disease: see colitis. , psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the , smoking cessation smoking cessation Public health Temporary or permanent halting of habitual cigarette smoking; withdrawal therapies–eg, hypnosis, psychotherapy, group counseling, exposing smokers to Pts with terminal lung CA and nicotine chewing gum are often ineffective. , and vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause. Market outlook: Short-term impact of the departure and arrival of patented blockbusters on select indications. Executive Summary Introduction Emerging Blockbusters to Treat Metabolic Disease metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome Merck's Januvia Novartis's Galvus Sanofi-Aventis's Acomplia Emerging Blockbusters to Treat Psychiatric Diseases Janssen's Paliperidone ER Wyeth's Pristiq Other Emerging Blockbusters Neurochem's Alzhemed AtheroGenics' Succinobucol (AGI-1067) UCB's Cimzia Conclusion Tables 1. Blockbuster Products Facing Patent Expiry by Mid 2008 2. Development Status and Anticipated Launch Year of Emerging Blockbusters Figures 1. Prevalent Cases of Metabolic Diseases, 2005 2. Market Value of Metabolic Diseases, 2005 3. Prevalent Cases of Schizophrenia and Depression, 2005 4. Market Value of Schizophrenia and Depression, 2005 5. Prevalent Cases of Chronic Heart Failure and Post-Myocardial Infarction, 2005 6. Market Value of Chronic Heart Failure and Post-Myocardial Infarction, 2005 7. Prevalent Cases of Chronic Inflammatory Diseases, 2005 8. Market Value of Chronic Inflammatory Diseases, 2005 Companies Mentioned: -Abbott Laboratories -Amgen -Amylin -AstraZeneca -AtheroGenics -Banyu -Centocor -Eisai -Eli Lilly -GlaxoSmithKline -Janssen -Johnson & Johnson -Merck -Neurochem -Neurocrine Biosciences -Novartis -Pfi zer -Sanofi -Aventis -Schering-Plough -Takeda -Tanabe -UCB -Wyeth For more information visit http://www.researchandmarkets.com/reports/c47802 Source: Decision Resources |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion